Elekta AB (publ) (OTCMKTS: EKTAY – Get Rating) and Biora Therapeutics (NASDAQ: BIOR – Get Rating) are both medical companies, but which is the better company? We’ll compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, and analyst recommendations.
Insider and Institutional Ownership
62.8% of Biora Therapeutics shares are held by institutional investors. 30.8% of the shares of Biora Therapeutics are held by insiders of the company. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.
Valuation and benefits
This table compares the revenue, earnings per share (EPS), and valuation of Elekta AB (publ) and Biora Therapeutics.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Elekta AB (publisher)||$1.57 billion||1.73||$143.46 million||$0.34||20.87|
|Biora Therapeutic||$1.25 million||101.66||-$247.41 million||($2.33)||-0.30|
Elekta AB (publ) has higher revenues and profits than Biora Therapeutics. Biora Therapeutics trades at a lower price-to-earnings ratio than Elekta AB (publ), indicating that it is currently the more affordable of the two stocks.
This is a summary of the current ratings of Elekta AB (publ) and Biora Therapeutics, as provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Elekta AB (publisher)||2||1||0||0||1.33|
|Biora Therapeutic||0||0||0||0||N / A|
Elekta AB (publ) currently has a consensus target price of $69.00, suggesting a potential upside of 872.52%. Given the likely higher upside of Elekta AB (publ), research analysts clearly believe that Elekta AB (publ) is more favorable than Biora Therapeutics.
This table compares the net margins, return on equity and return on assets of Elekta AB (publ) and Biora Therapeutics.
|Net margins||Return on equity||return on assets|
|Elekta AB (publisher)||7.74%||15.96%||5.13%|
|Biora Therapeutic||-19,288.71%||N / A||-130.02%|
Risk and Volatility
Elekta AB (publ) has a beta of 1.03, suggesting its stock price is 3% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.08, suggesting its stock price of its stock is 8% more volatile than the S&P 500. .
Elekta AB (publ) beats Biora Therapeutics on 8 of the 12 factors compared between the two stocks.
Company profile Elekta AB (publ) (Get a rating)
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiation therapy treatment systems, such as Versa HD, a precision dose delivery system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides custom imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. Additionally, the company offers radiosurgery systems under the names Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion and Elekta Axesse; Leksell GammaPlan, treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Additionally, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a communication tool with patients; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote post-loading platform; Esteya, electronic brachytherapy for the treatment of skin cancer; Oncentra Brachy, treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchi and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides the Leksell Vantage stereotactic system for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Biora Therapeutics Company Profile (Get a rating)
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapies. The Company’s Targeted Therapeutics Program uses an ingestible smart capsule for the targeted delivery of therapeutics to the gastrointestinal (GI) tract to improve the treatment of inflammatory bowel disease; and the systemic therapy program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic absorption. It also develops diagnostic devices to help characterize the gastrointestinal tract and diagnose gastrointestinal diseases, such as small intestinal bacterial overgrowth, through the development of various technologies to diagnose at the site of the sickness. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutic pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Receive daily news and reviews for Elekta AB (publ) – Enter your email address below to receive a concise daily summary of breaking news and analyst notes for Elekta AB (publ) and related companies with MarketBeat.com’s free daily email newsletter.